Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 27.07.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2020135556 - ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

Publication Number WO/2020/135556
Publication Date 02.07.2020
International Application No. PCT/CN2019/128585
International Filing Date 26.12.2019
IPC
C07K 16/18 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/46 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/6803
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
A61K 47/6817
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6811the drug being a protein or peptide, e.g. transferrin or bleomycin
6817Toxins
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
Applicants
  • 长春金赛药业有限责任公司 CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 冯晓 FENG, Xiao
  • 王涛 WANG, Tao
  • 金磊 JIN, Lei
  • 郭洪瑞 GUO, Hongrui
  • 刘爽 LIU, Shuang
  • 韩宁 HAN, Ning
  • 梁阳秋 LIANG, Yangqiu
  • 陈宇珩 CHEN, Yuheng
Agents
  • 北京集佳知识产权代理有限公司 UNITALEN ATTORNEYS AT LAW
Priority Data
201811620872.228.12.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
(FR) PROTÉINE DE FUSION D'ANTICORPS, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) 抗体融合蛋白、制备方法及其应用
Abstract
(EN)
Provided are an antibody fusion protein, a preparation method therefor and an application thereof. The antibody fusion protein is high in expression quantity, and the transient expression quantity in mammalian cells 293E is 100-150 mg/L; the antibody fusion protein is high in assembly rate, and the correct assembly rate exceeds 95%; the antibody fusion protein has a high affinity, and a single-sided antibody/fusion protein and antigen binding KD value is equivalent to a positive control monoclonal antibody/fusion protein and antigen binding KD value; the antibody fusion protein is convenient to purify, and the purity can reach more than 95% in one-step purification by using Protein A or Protein L, and the tumor inhibition rate in a pharmacodynamic experiment animal can reach up to 92%.
(FR)
La présente invention concerne une protéine de fusion d'anticorps, son procédé de préparation et son utilisation. La protéine de fusion d'anticorps présente une quantité d'expression élevée, et une quantité d'expression transitoire dans des cellules de mammifère 293E est de 100 à 150 mg/L; la protéine de fusion d'anticorps présente un taux d'assemblage élevé, et le taux d'assemblage exact dépasse 95 %; la protéine de fusion d'anticorps a une affinité élevée, et une valeur KD de liaison anticorps simple face/protéine de fusion et antigène est équivalente à une valeur KD de liaison anticorps monoclonal témoin positif/protéine de fusion et antigène; la protéine de fusion d'anticorps est pratique à purifier, et la pureté peut atteindre plus de 95 % dans une purification en une étape par utilisation d'une protéine A ou d'une protéine L, et le taux d'inhibition tumoral chez un animal d'expérience pharmacodynamique peut atteindre jusqu'à 92 %.
(ZH)
提供了抗体融合蛋白、制备方法及其应用。该抗体融合蛋白,表达量高,哺乳动物细胞293E中瞬转表达量100-150mg/L;装配率高,正确装配率超过95%;亲和力高,单边抗体/融合蛋白和抗原结合KD值与阳性对照单克隆抗体/融合蛋白和抗原结合KD值相当;便于纯化,使用Protein A或Protein L一步纯化纯度即可达到95%以上,药效实验动物体内抑瘤率最高可达92%。
Also published as
Latest bibliographic data on file with the International Bureau